Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes

Essam Mohamed, Amélie Bonnefond, Annelise Bennaceur-Griscelli, Philippe Froguel

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to differentiate into insulin-secreting β cells. Obtaining PSCs genetically identical to the patient presenting with diabetes has been a longstanding dream for the in vitro modeling of disease and ultimately cell therapy. For several years, somatic cell nuclear transfer (SCNT) was the method of choice to generate patient-specific ESC lines. However, this technology faces ethical and practical concerns. Interestingly, the recently established iPSC technology overcomes the major problems of other stem cell types including the lack of ethical concern and no risk of immune rejection. Several iPSC lines have been recently generated from patients with different types of diabetes, and most of these cell lines are able to differentiate into insulin-secreting β cells. In this review, we summarize recent advances in the differentiation of pancreatic β cells from PSCs, and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, we discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes.

Original languageEnglish
Pages (from-to)327-337
Number of pages11
JournalStem Cell Reviews and Reports
Volume10
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Pluripotent Stem Cells
Cell- and Tissue-Based Therapy
Embryonic Stem Cells
Insulin-Secreting Cells
Technology
Cell Line
Aptitude
Cell Differentiation
Diabetes Mellitus
Stem Cells
Incidence
In Vitro Techniques
Therapeutics

Keywords

  • Cell therapy
  • Diabetes mellitus
  • Embryonic stem cells (ESCs)
  • Induced pluripotent stem cells (iPSCs)
  • Insulin-secreting cells
  • Pancreatic β cells

ASJC Scopus subject areas

  • Cell Biology
  • Cancer Research

Cite this

Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes. / Mohamed, Essam; Bonnefond, Amélie; Bennaceur-Griscelli, Annelise; Froguel, Philippe.

In: Stem Cell Reviews and Reports, Vol. 10, No. 3, 01.01.2014, p. 327-337.

Research output: Contribution to journalArticle

Mohamed, Essam ; Bonnefond, Amélie ; Bennaceur-Griscelli, Annelise ; Froguel, Philippe. / Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes. In: Stem Cell Reviews and Reports. 2014 ; Vol. 10, No. 3. pp. 327-337.
@article{e743159920784fff86b2b5953e5b4d4f,
title = "Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes",
abstract = "Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to differentiate into insulin-secreting β cells. Obtaining PSCs genetically identical to the patient presenting with diabetes has been a longstanding dream for the in vitro modeling of disease and ultimately cell therapy. For several years, somatic cell nuclear transfer (SCNT) was the method of choice to generate patient-specific ESC lines. However, this technology faces ethical and practical concerns. Interestingly, the recently established iPSC technology overcomes the major problems of other stem cell types including the lack of ethical concern and no risk of immune rejection. Several iPSC lines have been recently generated from patients with different types of diabetes, and most of these cell lines are able to differentiate into insulin-secreting β cells. In this review, we summarize recent advances in the differentiation of pancreatic β cells from PSCs, and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, we discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes.",
keywords = "Cell therapy, Diabetes mellitus, Embryonic stem cells (ESCs), Induced pluripotent stem cells (iPSCs), Insulin-secreting cells, Pancreatic β cells",
author = "Essam Mohamed and Am{\'e}lie Bonnefond and Annelise Bennaceur-Griscelli and Philippe Froguel",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12015-014-9503-6",
language = "English",
volume = "10",
pages = "327--337",
journal = "Stem Cell Reviews",
issn = "1550-8943",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes

AU - Mohamed, Essam

AU - Bonnefond, Amélie

AU - Bennaceur-Griscelli, Annelise

AU - Froguel, Philippe

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to differentiate into insulin-secreting β cells. Obtaining PSCs genetically identical to the patient presenting with diabetes has been a longstanding dream for the in vitro modeling of disease and ultimately cell therapy. For several years, somatic cell nuclear transfer (SCNT) was the method of choice to generate patient-specific ESC lines. However, this technology faces ethical and practical concerns. Interestingly, the recently established iPSC technology overcomes the major problems of other stem cell types including the lack of ethical concern and no risk of immune rejection. Several iPSC lines have been recently generated from patients with different types of diabetes, and most of these cell lines are able to differentiate into insulin-secreting β cells. In this review, we summarize recent advances in the differentiation of pancreatic β cells from PSCs, and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, we discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes.

AB - Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to differentiate into insulin-secreting β cells. Obtaining PSCs genetically identical to the patient presenting with diabetes has been a longstanding dream for the in vitro modeling of disease and ultimately cell therapy. For several years, somatic cell nuclear transfer (SCNT) was the method of choice to generate patient-specific ESC lines. However, this technology faces ethical and practical concerns. Interestingly, the recently established iPSC technology overcomes the major problems of other stem cell types including the lack of ethical concern and no risk of immune rejection. Several iPSC lines have been recently generated from patients with different types of diabetes, and most of these cell lines are able to differentiate into insulin-secreting β cells. In this review, we summarize recent advances in the differentiation of pancreatic β cells from PSCs, and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, we discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes.

KW - Cell therapy

KW - Diabetes mellitus

KW - Embryonic stem cells (ESCs)

KW - Induced pluripotent stem cells (iPSCs)

KW - Insulin-secreting cells

KW - Pancreatic β cells

UR - http://www.scopus.com/inward/record.url?scp=84899938324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899938324&partnerID=8YFLogxK

U2 - 10.1007/s12015-014-9503-6

DO - 10.1007/s12015-014-9503-6

M3 - Article

VL - 10

SP - 327

EP - 337

JO - Stem Cell Reviews

JF - Stem Cell Reviews

SN - 1550-8943

IS - 3

ER -